{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nzl66q\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nzl66q\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/4\\\/16-a\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;15\\\/4\\\/16-a\u0022}],\u0022ac\u0022:{\u0022spmdc;15\\\/4\\\/16-a\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;15\\\/4\\\/16-a\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/cdn\/css\/http\/css_Xg7z6oCTVgud_Q0huYz9x9iiD5H_2YPSJ5z2ZViSWdY.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003ELiraglutide or roflumilast treatment of obese women with polycystic ovarian syndrome resulted in significant weight loss from baseline compared with metformin. In addition, liraglutide treatment decreased serum glucose levels before and after a 120-minute oral glucose tolerance test, whereas roflumilast treatment decreased free testosterone levels and the free androgen index.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003EPCOS\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epolycystic ovarian syndrome\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Emetformin\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eliraglutide\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eroflumilast\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003ENCT02187250\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eendocrinology, diabetes \u0026amp; metabolism clinical trials\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Epolycystic ovary disorder\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003Eobesity\u003C\/li\u003E\u003C\/ul\u003E\u003Cdiv class=\u0022section\u0022 id=\u0022sec-1\u0022\u003E\n         \n         \u003Cp id=\u0022p-2\u0022\u003ETreatment of obese women with polycystic ovarian syndrome (PCOS) with liraglutide or roflumilast, but not metformin, resulted in a significant decrease in body weight and improvement in metabolic and endocrine parameters. Mojca Jensterle, MD, University Medical Center Ljubljana, Ljubljana, Slovenia, presented data from the PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome trial [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT02187250\u0026amp;atom=%2Fspmdc%2F15%2F4%2F16.2.atom\u0022\u003ENCT02187250\u003C\/a\u003E].\u003C\/p\u003E\n         \u003Cp id=\u0022p-3\u0022\u003EWomen with PCOS struggle with weight loss, and weight reduction through lifestyle changes and pharmacotherapy such as metformin may improve cutaneous manifestations and menstrual cycle regularity and fertility and reduce cardiovascular disease factors. Potential alternatives to metformin include glucagon-like peptide-1 (GLP-1) receptor agonists [Kahal H et al. \u003Cem\u003EClin Endocrinol (Oxf)\u003C\/em\u003E. 2014; Elkind-Hirsch K et al. \u003Cem\u003EJ Clin Endocrinol Metab\u003C\/em\u003E. 2008] or PDE4 inhibitors, which increase GLP-1 plasma levels through completely different pathways involved in PDE4 regulation of signaling cascades linked to GLP-1 release [Vollert S et al. \u003Cem\u003EDiabetologia\u003C\/em\u003E. 2012; Wouters EF et al. \u003Cem\u003EJ Clin Endocrinol Metab\u003C\/em\u003E. 2012; Calverley PMA et al. \u003Cem\u003ELancet\u003C\/em\u003E. 2009].\u003C\/p\u003E\n         \u003Cp id=\u0022p-4\u0022\u003EThe purpose of this study was to determine if treatment of obese women with PCOS with liraglutide or roflumilast improved body weight compared with metformin. In this prospective, open-label, phase 4 trial, 45 obese women with PCOS were randomly assigned to receive metformin, liraglutide, or roflumilast for 12 weeks. At baseline, mean body mass index was 38.6\u2005\u00b1\u20056.0 kg\/m\u003Csup\u003E2\u003C\/sup\u003E, and mean age was 30.7\u2005\u00b1\u20057.9 years. Women were eligible if they had no significant cardiovascular, kidney, or hepatic disease; had no history of neuropsychiatric events; and did not use a medication known to affect reproductive or metabolic functions. The primary outcome of the study was changes in anthropometric measures of obesity.\u003C\/p\u003E\n         \u003Cp id=\u0022p-5\u0022\u003ECompared with baseline, patients who received liraglutide and roflumilast experienced a significant decrease in body weight of 3.1 kg (\u00b13.5 kg; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.006) and 2.1 kg (\u00b12.0 kg; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.002), respectively, whereas patients who received metformin did not experience a significant body weight loss (\u22120.1\u2005\u00b1\u20051.9 kg). In the liraglutide arm, but not the metformin or roflumilast arms, there was a significant decrease in visceral adipose tissue area from baseline (160.3\u2005\u00b1\u200567.9 cm\u003Csup\u003E2\u003C\/sup\u003E to 140.7\u2005\u00b1\u200560.8 cm\u003Csup\u003E2\u003C\/sup\u003E; \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.015).\u003C\/p\u003E\n         \u003Cp id=\u0022p-6\u0022\u003ESignificant improvement was detected in some metabolic and endocrine parameters among patients who received liraglutide and roflumilast. There was a significant decrease in mean serum glucose levels before and after a 120-minute oral glucose tolerance test in the liraglutide arm (\u003Cem\u003EP\u003C\/em\u003E\u2005\u2264\u2005.05 for both), but not the metformin or roflumilast arms. In the roflumilast arm, total testosterone levels and free androgen index significantly decreased from baseline (\u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.05 and \u003Cem\u003EP\u003C\/em\u003E\u2005=\u2005.016, respectively).\u003C\/p\u003E\n         \u003Cp id=\u0022p-7\u0022\u003EIn conclusion, Dr Jensterle stated that the results from this study suggest that treatment of obese women with PCOS with liraglutide was superior to metformin and roflumilast in the reduction of body weight and improvement in body composition, with roflumilast superior to metformin. However, treatment with roflumilast, but not metformin or liraglutide, reduced testosterone levels.\u003C\/p\u003E\n      \u003C\/div\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2015 SAGE Publications\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/15\/4\/16.2.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nzl66q\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}